Home › NDC Lookup › RxCUI directory › RxCUI 198352

Zidovudine 100 MG Oral Capsule — RxCUI 198352

RxNorm drug concept · Semantic clinical drug
RxCUI 198352 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI198352
Official nameZidovudine 100 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asAZT 100 MG Oral Capsule
FDA products mapped4
Package NDCs mapped5
Reported Medicaid activity (SDUD)46 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Zidovudine Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • The injectable form of Retrovir is used when you can't take medicine by mouth — for example, during surgery, labor, or if you're too unwell to swallow. It's given directly into a v...
  • Why am I getting zidovudine as an injection instead of a pill?
  • Yes — this is one of the most important uses of Retrovir. In a well-designed clinical study, treating HIV-positive mothers with zidovudine during pregnancy and labor, and then trea...
  • Can zidovudine really lower the chances of passing HIV to my baby?
📖 Read our full Zidovudine Injection guide →

🕸️ Concept Web — How Zidovudine 100 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Zidovudine 100 MG Oral Capsule RxCUI 198352

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Zidovudine 11413
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Retrovir 202791
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Zidovudine Oral Capsule 374331
    • Zidovudine Oral Product 1163028
    • Zidovudine Pill 1163029
    • Zidovudine Oral Capsule [Retrovir] 366687
    • Retrovir Oral Product 1182541
    • Retrovir Pill 1182542
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Zidovudine 100 MG SCDC · 316915
  • Zidovudine Oral Capsule SCDF · 374331
  • Zidovudine Oral Product SCDG · 1163028
  • Zidovudine Pill SCDG · 1163029

Brand-Name Concepts

  • Zidovudine 100 MG Oral Capsule [Retrovir] SBD · 201907
  • Zidovudine 100 MG [Retrovir] SBDC · 566052
  • Zidovudine Oral Capsule [Retrovir] SBDF · 366687
  • Retrovir Oral Product SBDG · 1182541
  • Retrovir Pill SBDG · 1182542
  • Retrovir BN · 202791

📦 FDA Products & Package NDCs

4 products · 5 package NDCs
5 package NDCs map to RxCUI 198352 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49702-0211-20 100 CAPSULE in 1 BOTTLE (49702-211-20) RETROVIR ViiV Healthcare Company 2010-10-28
49702-0212-48 240 mL in 1 BOTTLE (49702-212-48) RETROVIR ViiV Healthcare Company 2010-10-28
49702-0213-26 5 VIAL, SINGLE-USE in 1 CARTON (49702-213-26) / 20 mL in 1... RETROVIR ViiV Healthcare Company 2016-12-01
65862-0107-01 100 CAPSULE in 1 BOTTLE (65862-107-01) Zidovudine Aurobindo Pharma Limited 2006-03-27
65862-0107-10 10 BLISTER PACK in 1 CARTON (65862-107-10) / 10 CAPSULE in... Zidovudine Aurobindo Pharma Limited 2006-03-27
Observed labelers: ViiV Healthcare Company (3) · Aurobindo Pharma Limited (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J3485 Zidovudine 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.